Segall Bryant & Hamill, LLC Castle Biosciences Inc Transaction History

Segall Bryant & Hamill, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $90,715 - $138,309	4,030 Added 2.03%	202,344 $5.28 Million
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $944,432 - $2.71 Million	59,027 Added 42.38%	198,314 $4.35 Million
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $10,946 - $15,503	330 Added 0.24%	139,287 $6.25 Million
Q4 2021 Feb 14, 2022	BUY	$39.06 - $67.58 $2.64 Million - $4.57 Million	67,582 Added 94.69%	138,957 $5.96 Million
Q3 2021 Nov 03, 2021	BUY	$60.13 - $77.6 $116,351 - $150,156	1,935 Added 2.79%	71,375 $4.75 Million
Q2 2021 Aug 12, 2021	SELL	$50.07 - $76.78 $746,493 - $1.14 Million	-14,909 Reduced 17.68%	69,440 $5.09 Million
Q1 2021 May 13, 2021	BUY	$58.92 - $97.33 $1.07 Million - $1.76 Million	18,087 Added 27.3%	84,349 $5.77 Million
Q4 2020 Feb 12, 2021	SELL	$43.6 - $73.05 $52,625 - $88,171	-1,207 Reduced 1.79%	66,262 $4.45 Million
Q3 2020 Nov 13, 2020	BUY	$38.47 - $52.03 $2.6 Million - $3.51 Million	67,469 New	67,469 $3.47 Million

201

24.5M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $724M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.